CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for